RA
AVDL

Royce & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Royce & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,460
Closed -$278K – 790
2025
Q1 		$278K Hold
35,460
– – ﹤0.01% 760
2024
Q4 		$373K Hold
35,460
– – ﹤0.01% 777
2024
Q3 		$465K Hold
35,460
– – ﹤0.01% 805
2024
Q2 		$499K Sell
35,460
-13,102
-27% -$214K ﹤0.01% 790
2024
Q1 		$820K Buy
48,562
+27,581
+131% +$411K 0.01% 746
2023
Q4 		$296K Buy
+20,981
New +$246K ﹤0.01% 825

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's AVDL Position: Q2 2025 in Review

Royce & Associates sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 35,460 shares — an estimated $278K sold.

Royce & Associates first reported a position in AVDL in Q4 2023 and held it in 6 quarters. The position peaked at $820K in Q1 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Royce & Associates reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Royce & Associates sold 35,460 Avadel Pharmaceuticals shares in Q2 2025, an estimated $278K.
  • Royce & Associates first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Royce & Associates's Avadel Pharmaceuticals position peaked at $820K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Royce & Associates's 13F filing for Q2 2025, filed 11 Aug 2025.